Tscan Therapeutics Inc (TCRX) - Net Assets
Based on the latest financial reports, Tscan Therapeutics Inc (TCRX) has net assets worth $123.12 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($228.79 Million) and total liabilities ($105.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tscan Therapeutics Inc (TCRX) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $123.12 Million |
| % of Total Assets | 53.82% |
| Annual Growth Rate | 19.37% |
| 5-Year Change | -23.42% |
| 10-Year Change | N/A |
| Growth Volatility | 93.66 |
Tscan Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Tscan Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Tscan Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Tscan Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Tscan Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see Tscan Therapeutics Inc (TCRX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $123.12 Million | -48.91% |
| 2024-12-31 | $240.97 Million | +59.72% |
| 2023-12-31 | $150.87 Million | +51.73% |
| 2022-12-31 | $99.43 Million | -38.15% |
| 2021-12-31 | $160.78 Million | +478.64% |
| 2020-12-31 | $-42.46 Million | -199.81% |
| 2019-12-31 | $42.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tscan Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48745600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Components | $627.98 Million | 510.04% |
| Total Equity | $123.12 Million | 100.00% |
Tscan Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Tscan Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nh Prime Reit Co Ltd
KO:338100
|
$60.32 Million |
|
Spruce Power Holding Corp
NYSE:SPRU
|
$60.32 Million |
|
Fairvest Ltd
JSE:FTA
|
$60.33 Million |
|
DCC plc
LSE:DCC
|
$60.33 Million |
|
Coffee Day Enterprises Limited
NSE:COFFEEDAY
|
$60.31 Million |
|
PBG S.A
SA:PTBL3
|
$60.31 Million |
|
Essar Shipping Limited
NSE:ESSARSHPNG
|
$60.30 Million |
|
iFabric Corp
TO:IFA
|
$60.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tscan Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 240,970,000 to 123,123,000, a change of -117,847,000 (-48.9%).
- Net loss of 129,766,000 reduced equity.
- Share repurchases of 264,000 reduced equity.
- Other comprehensive income decreased equity by 51,000.
- Other factors increased equity by 12,234,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-129.77 Million | -105.4% |
| Share Repurchases | $264.00K | -0.21% |
| Other Comprehensive Income | $-51.00K | -0.04% |
| Other Changes | $12.23 Million | +9.94% |
| Total Change | $- | -48.91% |
Book Value vs Market Value Analysis
This analysis compares Tscan Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.72x to 1.29x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.71 | $1.22 | x |
| 2020-12-31 | $-1.70 | $1.22 | x |
| 2021-12-31 | $6.72 | $1.22 | x |
| 2022-12-31 | $4.13 | $1.22 | x |
| 2023-12-31 | $2.30 | $1.22 | x |
| 2024-12-31 | $2.15 | $1.22 | x |
| 2025-12-31 | $0.95 | $1.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tscan Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -105.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1256.81%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.86x
- Recent ROE (-105.40%) is below the historical average (-49.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -32.10% | 0.00% | 0.00x | 1.16x | $-17.91 Million |
| 2020 | 0.00% | -2408.02% | 0.02x | 0.00x | $-21.88 Million |
| 2021 | -30.24% | -479.49% | 0.05x | 1.17x | $-64.70 Million |
| 2022 | -66.60% | -489.26% | 0.07x | 2.00x | $-76.16 Million |
| 2023 | -59.14% | -423.86% | 0.08x | 1.80x | $-104.30 Million |
| 2024 | -52.91% | -4527.66% | 0.01x | 1.54x | $-151.60 Million |
| 2025 | -105.40% | -1256.81% | 0.05x | 1.86x | $-142.08 Million |
Industry Comparison
This section compares Tscan Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tscan Therapeutics Inc (TCRX) | $123.12 Million | -32.10% | 0.86x | $60.32 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Tscan Therapeutics Inc
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic… Read more